Daptomycin Companies

Latest Daptomycin Companies Update

August 2023: Camber Pharmaceuticals is now providing Daptomycin for Injection in two different strengths, namely 350 mg and 500 mg, as generic alternatives. Daptomycin for intravenous administration is a lipopeptide antimicrobial agent that is prescribed for the management of complex skin and skin structure infections in both adult and pediatric populations, encompassing individuals ranging from 1 to 17 years of age. Daptomycin for Injection 500 mg is the generic equivalent of the medication known as Cubicin. Daptomycin for Injection is offered in single-dose vials with dosages of 350 mg and 500 mg.

September 2023: Researchers reported in The New England Journal of Medicine that the Swiss pharmaceutical company Basilea Pharmaceutica's ceftobiprole appeared to be as effective as the older drug daptomycin in the approximately one-fourth of patients with particularly difficult to treat methicillin-resistant S aureus (MRSA) infections. Data from a late-stage experiment showed that an antibiotic already in use in Europe to treat pneumonia was just as efficient as the most potent antibiotic presently available in controlling dangerous bloodstream infections caused by Staphylococcus aureus germs.  For more than 15 years, there has been no new antibiotic licensed for the treatment of S aureus bacteremia. For the trial, 390 patients hospitalized with serious bloodstream staph infections were randomly randomized to receive infusions of ceftobiprole or daptomycin. According to the data, the therapy was effective in 69.8 percent of the ceftobiprole group and in 68.7 percent of the daptomycin group.

• Teva Pharmaceuticals Industries Ltd.


• Merck & Co.


• Cipla


• Pfizer


• BE Pharmaceuticals


• Reddy’s Laboratories


• Mylan


• Fresenius Kabi


• Nichi-Iko Pharmaceutical


• Novo Holdings A/S


• Zhejiang Hisun